Abiomed Announces Publication of Protect II Cost Effectiveness Study in American Health & Drug Benefits Journal

Abiomed Announces Publication of Protect II Cost Effectiveness Study in
American Health & Drug Benefits Journal

Economic Study Demonstrates Cost Effectiveness of Impella

DANVERS, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a
leading provider of breakthrough heart support technologies, today announced
the publication of the PROTECT II Cost Effectiveness Study in the American
Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of
Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing
a Percutaneous Coronary Intervention."

The study demonstrated a gain in quality of life for Impella patients over the
current standard of care, the intra-aortic balloon pump (IABP), at an
incremental cost-effectiveness ratio (ICER) of $39,389/QALY (Quality Adjusted
Life Year), well below the $100,000/QALY threshold commonly used in the United
States or the $50,000/QALY threshold of dialysis.

PROTECT II was the first multicenter, randomized trial comparing non-emergent
use of hemodynamic support in patients with depressed left ventricular
function and complex anatomy that analyzed both the clinical and economic
benefits of hemodynamic support. The clinical trial outcomes data and actual
billing data from patients were modeled over ten years using a Markov Model to
derive the ICER/QALY.

"This study indicates that new, minimally invasive technologies like Impella
provide the opportunity for increased quality care and shared savings
opportunities for all stakeholders. As the heart failure population
proliferates, decision-makers will need to understand and balance the
short-term costs of procedures versus the long-term costs for ongoing care,"
said David Gregory, MPA, FACHE, author of the study and Executive Vice
President and Partner, Presscott Associates - A Division of ParenteBeard, LLC.

"We are very excited about the continued expansion of compelling
cost-effectiveness data for the Impella platform, which helps providers and
payers navigate the evolving landscape of health care reform," said Michael R.
Minogue, Chairman, President and Chief Executive Officer of Abiomed.

The American Health & Drug Benefits (AHDB) is an independent, peer-reviewed
journal founded in 2008 on the concept that health and drug benefits have
undergone a transformation: the econometric value of a therapy is currently of
equal importance to clinical outcomes as it is to serving as the basis for
coverage decisions and benefit designs.

The publication of this PROTECT II Cost Effectiveness study is one of several
published or presented data sets from 2012-2013 that all demonstrate the cost
effectiveness of Impella.


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support.Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com


This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently filed
Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.

CONTACT: For further information please contact:
         Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         Aimee Genzler
         Corporate Communications Manager

Abiomed Logo
Press spacebar to pause and continue. Press esc to stop.